Neurocrine Biosciences, Inc. (NBIX) Stock
NBIX Key Statistics
About Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. is a pharmaceutical firm dedicated to the creation, advancement, and commercialization of medicines addressing a spectrum of neurological, endocrine, and psychiatric conditions. Its current therapeutic pipeline and marketed products target disorders such as tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, alongside numerous experimental compounds in various clinical stages. The company's primary commercial asset is INGREZZA, a VMAT2 inhibitor indicated for the management of tardive dyskinesia. Other available treatments include ONGENTYS, which serves as an auxiliary therapy for individuals with Parkinson's disease who are also receiving levodopa/DOPA decarboxylase inhibitors; ORILISSA, prescribed for the alleviation of moderate to severe pain linked with endometriosis in women; and ORIAHNN, an oral, non-surgical option for pre-menopausal women experiencing significant menstrual bleeding associated with uterine fibroids. Furthermore, Neurocrine is actively progressing a number of drug candidates through clinical development. These include NBI-921352 for treating pediatric patients and adult focal epilepsy; NBI-827104, designed to address rare pediatric epilepsy and essential tremor; NBI-1065845 for major depressive disorder; NBI-1065846 specifically for anhedonia within major depressive disorder; and NBI-118568 for the treatment of schizophrenia. The company also maintains strategic licensing and collaborative ventures with partners such as Heptares Therapeutics Limited, Takeda Pharmaceutical Company Limited, Idorsia Pharmaceuticals Ltd, Xenon Pharmaceuticals Inc., Voyager Therapeutics, Inc., BIAL Portela & Ca, S.A., Mitsubishi Tanabe Pharma Corporation, and AbbVie Inc. Neurocrine Biosciences, Inc. was founded in 1992 and operates from its headquarters in San Diego, California.
CEO: Kyle W. Gano. Company website
NBIX — Frequently Asked Questions
What is the NBIX stock price today?
Neurocrine Biosciences, Inc. (NBIX) trades at $174.41, up 3.12% on the day, as of Nov 12, 2026 09:32 UTC.
What is Neurocrine Biosciences, Inc.'s market cap?
Neurocrine Biosciences, Inc. has a market capitalisation of $17.65B, calculated from the live NBIX share price and shares outstanding.
What is the P/E ratio of NBIX?
NBIX trades at a trailing P/E of 25.88, from earnings per share of $6.74 over the last twelve months.
How much revenue does Neurocrine Biosciences, Inc. make?
Neurocrine Biosciences, Inc. generated revenue of $3.70B over the trailing twelve months, which puts the stock at 4.77 times sales.
What is the 52-week range for NBIX?
NBIX has traded between $122.15 and $186.12 over the past 52 weeks, and the last price is 6.3% below that high.
Is Neurocrine Biosciences, Inc. profitable?
Yes. Neurocrine Biosciences, Inc. keeps 18.98% of revenue as net income over the trailing twelve months.
What is the analyst price target for NBIX?
Wall Street analysts rate NBIX Buy, with an average price target of $203.41, 16.6% above the current price.
What sector is Neurocrine Biosciences, Inc. in?
Neurocrine Biosciences, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US.
Who is the CEO of Neurocrine Biosciences, Inc.?
Kyle W. Gano is the chief executive of Neurocrine Biosciences, Inc., which employs 2,500 people.
Where can I track NBIX in real time?
QFI Terminal shows NBIX with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See NBIX live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open NBIX in Terminal See plans